BACKGROUND: We recently reported that human blood dendritic cells from allergic subjects have impaired IFN-alpha production following toll-like receptor 9 (TLR9)-dependent innate immune stimulation. It is not known how subcutaneous allergen immunotherapy (SCIT) affects dendritic cell immune responses. OBJECTIVE: The aim of this study is to determine how SCIT affects human dendritic cell function. METHODS: Peripheral blood mononuclear cell (PBMC) and plasmacytoid dendritic cells (pDCs) were isolated from the blood of seven dust mite allergic subjects at baseline and upon reaching a standard SCIT maintenance dose that included dust mite and other aeroallergens. Cells were stimulated with various adaptive and innate immune receptor stimuli, or media alone for 20 h with secreted cytokine levels determined by ELISA. A portion of the cells were used to measure intracellular signalling proteins by flow cytometry. Humoral immune responses were measured from plasma. RESULTS: SCIT resulted in a threefold increase in PBMC production of IFN-alpha in response to CpG at 100 nM (P=0.015) and at 500 nM (P=0.015), n=7. The predominant cell type known to produce IFN-alpha in response to CpG (CpG ODN-2216) and other TLR9 agonists is the pDC. As expected, a robust innate immune response from isolated pDCs was re-established among allergic subjects undergoing SCIT resulting in a fivefold increase in IFN-alpha production in response to CpG at 500 nM (P=0.046), n=7. In contrast, IL-6 production was unaffected by SCIT (P=0.468). Consistent with published reports, IgG4 blocking antibody increased 10-fold with SCIT (P=0.031), n=7. There was no significant increase in the frequency of pDCs or the expression of TLR9 that would account for the rise in IFN-alpha production. CONCLUSIONS: Allergen immunotherapy increases dendritic cell TLR9-mediated innate immune function, which has previously been shown to be impaired at baseline in allergic subjects.
BACKGROUND: We recently reported that human blood dendritic cells from allergic subjects have impaired IFN-alpha production following toll-like receptor 9 (TLR9)-dependent innate immune stimulation. It is not known how subcutaneous allergen immunotherapy (SCIT) affects dendritic cell immune responses. OBJECTIVE: The aim of this study is to determine how SCIT affects human dendritic cell function. METHODS: Peripheral blood mononuclear cell (PBMC) and plasmacytoid dendritic cells (pDCs) were isolated from the blood of seven dust mite allergic subjects at baseline and upon reaching a standard SCIT maintenance dose that included dust mite and other aeroallergens. Cells were stimulated with various adaptive and innate immune receptor stimuli, or media alone for 20 h with secreted cytokine levels determined by ELISA. A portion of the cells were used to measure intracellular signalling proteins by flow cytometry. Humoral immune responses were measured from plasma. RESULTS: SCIT resulted in a threefold increase in PBMC production of IFN-alpha in response to CpG at 100 nM (P=0.015) and at 500 nM (P=0.015), n=7. The predominant cell type known to produce IFN-alpha in response to CpG (CpG ODN-2216) and other TLR9 agonists is the pDC. As expected, a robust innate immune response from isolated pDCs was re-established among allergic subjects undergoing SCIT resulting in a fivefold increase in IFN-alpha production in response to CpG at 500 nM (P=0.046), n=7. In contrast, IL-6 production was unaffected by SCIT (P=0.468). Consistent with published reports, IgG4 blocking antibody increased 10-fold with SCIT (P=0.031), n=7. There was no significant increase in the frequency of pDCs or the expression of TLR9 that would account for the rise in IFN-alpha production. CONCLUSIONS: Allergen immunotherapy increases dendritic cell TLR9-mediated innate immune function, which has previously been shown to be impaired at baseline in allergic subjects.
Authors: James N Francis; Louisa K James; Giannis Paraskevopoulos; Cheukyee Wong; Moises A Calderon; Stephen R Durham; Stephen J Till Journal: J Allergy Clin Immunol Date: 2008-04-18 Impact factor: 10.793
Authors: Trong Le; Jody Tversky; Kristin L Chichester; Anja P Bieneman; Shau-Ku Huang; Robert A Wood; John T Schroeder Journal: J Allergy Clin Immunol Date: 2008-10-09 Impact factor: 10.793
Authors: Lisa C Zaba; Judilyn Fuentes-Duculan; Narat John Eungdamrong; Maria Veronica Abello; Inna Novitskaya; Katherine C Pierson; Juana Gonzalez; James G Krueger; Michelle A Lowes Journal: J Invest Dermatol Date: 2008-07-17 Impact factor: 8.551
Authors: J R Tversky; T V Le; A P Bieneman; K L Chichester; R G Hamilton; J T Schroeder Journal: Clin Exp Allergy Date: 2008-03-01 Impact factor: 5.018
Authors: X Zhu; G Meng; B L Dickinson; X Li; E Mizoguchi; L Miao; Y Wang; C Robert; B Wu; P D Smith; W I Lencer; R S Blumberg Journal: J Immunol Date: 2001-03-01 Impact factor: 5.422
Authors: Pamela A Frischmeyer-Guerrerio; Corinne A Keet; Anthony L Guerrerio; Kristin L Chichester; Anja P Bieneman; Robert G Hamilton; Robert A Wood; John T Schroeder Journal: Clin Immunol Date: 2014-08-27 Impact factor: 3.969
Authors: Nancy E Lange; Xiaobo Zhou; Jessica Lasky-Su; Blanca E Himes; Ross Lazarus; Manuel Soto-Quirós; Lydiana Avila; Juan C Celedón; Catherine M Hawrylowicz; Benjamin A Raby; Augusto A Litonjua Journal: BMC Med Genet Date: 2011-02-15 Impact factor: 2.103